DXCM DEXCOM INC Insider Trading

Executive Chair Kevin R Sayer sold 26,756 shares of DXCM at $72.00 under 10b5-1 plan; remains holder of 355,726 shares

Kevin R Sayer sold 26.8K shares at $72.00, reducing his DXCM holdings by -7.0% to 355.7K shares. The sale was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. Dexcom's fundamentals show solid performance with $1.2B revenue, net income of $199.5M, and annual revenue growth of +15.6%, with the stock currently at $73.57 and a P/E of 30.53. Historical context shows Sayer's five prior DXCM sales yielded mixed post-trade outcomes: his 90-day returns at this ticker ranged from -18.0% to +20.5%, while his cross-ticker average 90-day return across 11 prior sells was -8.7%. This transaction carries low significance as it reflects a pre-planned divestiture rather than a discretionary decision, and Sayer retains substantial holdings.

Executive Chair Kevin R Sayer sold 26,759 shares (26.8K) of DXCM at $72.00 on 2026-05-21 under pre-arranged 10b5-1 plan; retains 382,482 shares.

Kevin R Sayer sold 26,759 shares of DEXCOM at $72.00 under a pre-arranged 10b5-1 trading plan, reducing his holdings by 6.5% to 382,482 shares while retaining a substantial position of 382.5K shares. The sale is scheduled per a 10b5-1 plan and therefore not discretionary. His prior trades at DXCM show mixed near-term outcomes (5 prior sales ranging from -6.0% to +20.5% in 30-day returns), and his cross-ticker track record shows an average 90-day return of -10.6% following sells, though the current price of $72.01 is -20.0% from the 52-week high and +17.0% over the past 30 days. The company posted $1,191,900,000.00 in revenue and $199,500,000.00 in net income in the latest quarter, with annual revenue growth of +15.6% and a P/E of 29.88.

DXCM President & COO Leach buys 18.2K shares for $1.0M on 2025-11-10; stock down 39.6% from 52-week high

Leach Jacob Steven, President & COO of Dexcom, executed two separate purchases on 2025-11-10 totaling 18,200 shares for $1,001,701.90 at a blended average price of $55.04, increasing his holdings by 5.8%. The transaction occurred as the stock trades at $54.84, down 39.6% from its 52-week high of $90.75 and down 15.8% over the prior 30 days. Leach's prior trading record at DXCM shows mixed outcomes: his three prior sales (2025-03-12, 2024-03-12, 2023-04-20) produced a 90-day well-timed rate of 33.33%, with only 1 of 3 sales being well-timed at the 90-day horizon. The company reports strong fundamentals with revenue of $1,209,300,000.00, net income of $283,800,000.00, and 11.3% annual revenue growth, though trading at a P/E of 29.64. The magnitude of this buy—$1.0M—and its execution during a period of substantial stock decline merit monitoring for signals about management's assessment of valuation at these depressed price levels.

EVP/CLO Brown sold 10,000 DXCM shares at $84.28 on 2025-05-23; stock now at $86.98 (-31.9% from 52-week high).

Brown Michael Jon, EVP and Chief Legal Officer, sold 10,000 shares of DEXCOM at $84.28, reducing his holdings by 9.5% to 95,602 shares. The sale occurred while the stock was trading significantly below its 52-week high of $127.64, though it has recovered 22.2% over the past 30 days. Across his prior open-market sales at all tickers, Brown's 90-day timing rate was 100%, and at DXCM specifically, 1 of 1 prior sales at the 90-day mark showed negative returns, indicating his historical sales have occurred before subsequent declines. This sale by a senior legal officer represents a reduction in skin-in-the-game at a $34.1B company trading at a P/E of 63.96.